---
title: Treatment forÂ JAK2Â + PV
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[polycythemia vera (PV)]]

# Treatment forÂ JAK2Â + PV

- **Phlebotomy**Â to goal Hct <45%Â (NEJMÂ 2013;368:22), consider <42% in women
- **Low-dose ASA**Â in all PtsÂ (NEJMÂ 2004;350:114)
- **Hydroxyurea**Â if high risk of thrombosis (age â‰¥60, prior thrombosis) or if inadequate Hct by phlebotomy alone
- [[PEG IFN-alpha]] preferred in younger Pts and pregnancyÂ (Lancet Haematol2017;4:e165)
- Ruxolitinib (JAK1/2 inhibitor) if refractory to or intolerant of hydroxyureaÂ (NEJMÂ 2015;372:426)
- Supportive: allopurinol (gout), H2-blockers/antihistamines (pruritus). Avoid iron supp.
- Data for optimal mgmt of other types of PV (secondary, germline, etc.) currently lacking
